[Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
Bernard M. Simon, Peter K Müller, Dammann Hg
Abstract
Bernard M. Simon, Peter K Müller, Dammann Hg
Abstract
Ranitidine and oxmetidine are newly developed histamine H2-receptor antagonists without any antiandrogenic activity and probably without drug interactions. In numerous clinical trials ranitidine has been proven to be at least as effective as cimetidine in the short- and long-term treatment of peptic ulcer disease. Ranitidine was found to be remarkably safe. Its therapeutic use in man should not be associated with significant adverse reactions.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Ranitidine and oxmetidine are newly developed histamine H2-receptor antagonists without any antiandrogenic activity and probably without drug interactions. In numerous clinical trials ranitidine has been proven to be at least as effective as cimetidine in the short- and long-term treatment of peptic ulcer disease. Ranitidine was found to be remarkably safe. Its therapeutic use in man should not be associated with significant adverse reactions.
Key concepts: Ranitidine, Medicine, Cimetidine, Histamine H2 receptor, Peptic ulcer, Histamine, Adverse effect, Disease